Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: AMRN stock price vs SWKS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at SWKS's multiple
Needs SWKS P/S.
Implied fair value · at AMRN's multiple
Needs AMRN P/S.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
SKYWORKS SOLUTIONS, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
ANALOG DEVICES INC
AMRN vs ADI
TEXAS INSTRUMENTS INC
AMRN vs TXN
QUALCOMM INC/DE
AMRN vs QCOM
Broadcom Inc.
AMRN vs AVGO
MICROCHIP TECHNOLOGY INC
AMRN vs MCHP
APPLIED MATERIALS INC /DE
AMRN vs AMAT
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMRN can reverse its negative revenue growth and convert its 56.6% gross margin into durable operating profit, then hold only with caution; otherwise, SWKS-relative data favors reducing exposure because AMRN trades at a steep premium to SWKS despite materially weaker profitability and returns.
AMRN trades at 32.2x P/S versus SWKS at 2.3x, yet AMRN generates only $213.6M of revenue and is loss-making, which makes the current price hard to justify on SWKS-relative valuation. The implied price of $1.19 versus the current $16.37 suggests -92.8% downside, although the stock is still inside its historical band of $14.73 to $18.01.
Supporting Metrics
